Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT03587194 Not yet recruiting - Psoriasis Clinical Trials

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

Start date: July 15, 2018
Phase: Phase 4
Study type: Interventional

Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8, non responders will be discontinued, partial responders will be given add-on Enstilar QD for 4 weeks and PASI 75 responders will remain on Otezla monotherapy through week 16.

NCT ID: NCT03584360 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin

Microbiome&Pso
Start date: July 2018
Phase: Phase 2
Study type: Interventional

Changes in microbiome have been reported recently in psoriasis lesions compared to healthy surround skin. Preliminary data showed that systemic treatments of psoriasis induce modification of the skin microbiome that becomes similar to healthy individuals after successful treatment. The causative role of microbiome in psoriasis remains in debate. The modification of skin microbiome is suspected to be able to activate the innate immune response, namely natural killers (NKs) and immune lymphoid cells (ILCs). Three types of ILCs have been reported. ILC1 (immune lymphoid cells1) that trigger a Th1 response, ILC2 (immune lymphoid cells 2) that stimulate Th2 response and ILC3 (immune lymphoid cells 3) that induce Th17 response. Interestingly, ILC2 have been reported to be increased in atopic dermatitis while ILC3 are increased in psoriasis.

NCT ID: NCT03580278 Not yet recruiting - Psoriasis Clinical Trials

A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

Start date: July 2018
Phase: Phase 1
Study type: Interventional

The purpose of this first-in-human study of the formulation ABY-035/AFO2 is to investigate the safety, tolerability and efficacy after multiple doses in sequential escalating dose cohorts in psoriasis subjects.

NCT ID: NCT03577626 Not yet recruiting - Psoriasis Clinical Trials

A Food Effect Study to Assess Pharmacokinetics of Hemay005 in Healthy Volunteers

Start date: October 10, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of food on the PK of a single dose of 52.5 mg Hemay005 in healthy subjects.

NCT ID: NCT03573323 Not yet recruiting - Plaque Psoriasis Clinical Trials

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

IXORA-R
Start date: November 12, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.

NCT ID: NCT03570346 Not yet recruiting - Psoriasis Clinical Trials

Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects

Start date: July 24, 2018
Phase: Phase 1
Study type: Interventional

Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. A total of approximately 24 subjects will be randomized into 3 cohorts(15mg, 30mg, 60mg), approximately 8 healthy subjects will be enrolled (6 active and 2 placebo) at each dose cohort. This study includes an 28-day Screening Period, a 1-day single dose and 7-days multiple doses Treatment Period, and an End of Study Visit occurring approximately 11days (±3 days) after study drug administration.

NCT ID: NCT03556202 Not yet recruiting - Psoriasis Clinical Trials

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Start date: September 25, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

NCT ID: NCT03553823 Not yet recruiting - Clinical trials for Chronic Plaque-type Psoriasis

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

ARROW
Start date: September 3, 2018
Phase: Phase 2
Study type: Interventional

The aim of this study is to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic plaques that remain active despite treatment with the non-selective IL-23 inhibitor ustekinumab (blocker of p40 subunit, shared by IL-12 and IL 23).

NCT ID: NCT03553433 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis

APRESCALP
Start date: June 2018
Phase: Phase 4
Study type: Interventional

A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis

NCT ID: NCT03542994 Recruiting - Psoriasis Clinical Trials

A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

Start date: April 24, 2018
Phase: Phase 1
Study type: Interventional

Evelo will investigate the safety and tolerability of EDP1066 and its potential to be a medicinal product in healthy volunteers and individuals with mild to moderate psoriasis and atopic dermatitis.